PKG Health believes every person with a neurological condition deserves to live their best life every day. We leverage the world’s largest body of clinical evidence in neurology, to create and deliver precision medicine by accelerating the research, approval and adoption of treatments. Its lead product, the Parkinson's KinetiGraph®(PKG® or Personal KinetiGraph® in the US), has been developed by neurologists at the world-renowned Florey Institute of Neuroscience in Melbourne, Australia. The PKG® enables the precise monitoring, quantification and reporting of movement patterns of neurological diseases including bradykinesia, dyskinesia, tremor and immobility. Our PKG technology: • Technically de-risked and established in market – over 6,000,000 hours of continuous Parkinson’s monitoring delivered to date, representing more than 25,000 patient PKGs • Changes clinical decisions more than 50% of the time • Boasts significant key opinion leader support • Is underpinned by robust clinical validation and regulatory clearance through FDA 510(k) in the USA, CE mark in Europe, TGA Class IIA ARTG 236583 listed The PKG® system is being used in clinics across the U.S., Europe and Asia Pacific, enabling better clinical outcomes and reducing health care costs across the Parkinson’s disease continuum. GK continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure the efficacy of new and advanced therapies for one of the world’s most widespread movement disorders. For further information, please visit our website, www.pkgcare.com
